Advertisement

Pilot Randomized Controlled Trial of a Syndemics Intervention with HIV-Positive, Cocaine-Using Women

  • Danita Jemison
  • Sequoia Jackson
  • Olorunleke Oni
  • Deva Cats-Baril
  • Shawdae Thomas-Smith
  • Abigail Batchelder
  • Allan Rodriguez
  • Samantha E. Dilworth
  • Lisa R. Metsch
  • Deborah Jones
  • Daniel J. Feaster
  • Conall O’Cleirigh
  • Gail Ironson
  • Adam W. CarricoEmail author
Original Paper

Abstract

This pilot randomized controlled trial examined the feasibility and acceptability of a Syndemics intervention targeting the intersection of stimulant use, trauma, and difficulties with HIV disease management in cocaine-using women. All participants received contingency management (CM) for 3 months with financial incentives for stimulant abstinence during thrice-weekly urine screening and refilling antiretroviral medications monthly. Sixteen participants were randomized to complete four expressive writing (n = 9) or four neutral writing (n = 7) sessions delivered during the CM intervention period. Completion rates for writing sessions were high (15 of 16 women completed all four sessions) and engagement in CM urine screening was moderate with women randomized to expressive writing providing a median of 11 non-reactive urine samples for stimulants. There were non-significant trends for those randomized to expressive writing to provide more CM urine samples that were non-reactive for stimulants, report greater decreases in severity of cocaine use, and display reductions in log10 HIV viral load at 6 months. Although the Syndemics intervention was feasible and acceptable to many women, qualitative interviews with eligible participants who were not randomized identified structural and psychological barriers to engagement. Further clinical research is needed to test the efficacy of Syndemics interventions with HIV-positive, cocaine-using women.

Keywords

Cocaine Contingency management Expressive writing Syndemics Viral load 

Notes

Acknowledgements

This project was supported by a pilot award from the Miami Center for AIDS Research (P30-AI073961; Pahwa, PI). Additional support was provided by the Center for HIV and Research in Mental Health (P30-MH116867; Safren, PI). We would also like to thank Ms. Arnetta Phillips for coordinating recruitment efforts for this project. We are grateful to Dr. Ranjini Valiathan for her support in conducting assays to measure CD4+ T-cell count and HIV viral load. Finally, we would like to thank Ji-Young Lee, Todd Jackson, Catherine Zaw, Jared Lee, and Erin Collier for their assistance in implementing the research protocol. Most importantly, we are grateful to the study participants who placed a great deal of trust in our team for this project.

References

  1. 1.
    Bing EG, Burnam M, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus–infected adults in the united states. Arch Gen Psychiatry. 2001;58(8):721–8.Google Scholar
  2. 2.
    Gamarel KE, Brown L, Kahler CW, Fernandez MI, Bruce D, Nichols S, et al. Prevalence and correlates of substance use among youth living with HIV in clinical settings. Drug Alcohol Depend. 2016;169:11–8.Google Scholar
  3. 3.
    Carrico AW, Hunt PW, Neilands TB, Dilworth SE, Martin JN, Deeks SG, et al. Stimulant use and viral suppression in the era of universal antiretroviral therapy. J Acquir Immune Defic Syndr. 2019;80:89–93.Google Scholar
  4. 4.
    Carrico AW, Johnson MO, Moskowitz JT, Neilands TB, Morin SF, Charlebois ED, et al. Affect regulation, stimulant use, and viral load among HIV-positive persons on anti-retroviral therapy. Psychosom Med. 2007;69(8):785–92.Google Scholar
  5. 5.
    Carrico AW, Riley ED, Johnson MO, Charlebois ED, Neilands TB, Remien RH, et al. Psychiatric risk factors for HIV disease progression: the role of inconsistent patterns of antiretroviral therapy utilization. J Acquir Immune Defic Syndr. 2011;56(2):146–50.Google Scholar
  6. 6.
    Carrico AW, Shoptaw S, Cox C, Stall R, Li X, Ostrow DG, et al. Stimulant use and progression to AIDS or mortality after the initiation of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;67(5):508–13.Google Scholar
  7. 7.
    Cook JA, Burke-Miller JK, Cohen MH, Cook RL, Vlahov D, Wilson TE, et al. Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS. 2008;22(11):1355–63.Google Scholar
  8. 8.
    Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction. 2006;101(11):1546–60.Google Scholar
  9. 9.
    Petry NM, Weinstock J, Alessi SM, Lewis MW, Dieckhaus K. Group-based randomized trial of contingencies for health and abstinence in HIV patients. J Consult Clin Psychol. 2010;78(1):89–97.Google Scholar
  10. 10.
    Metsch LR, Feaster DJ, Gooden L, Matheson T, Stitzer M, Das M, et al. Effect of patient navigation with or without financial incentives on viral suppression among hospitalized patients with HIV infection and substance use: a randomized clinical trial. JAMA. 2016;316(2):156–70.Google Scholar
  11. 11.
    Carrico AW, Gomez W, Jain J, Shoptaw S, Discepola MV, Olem D, et al. Randomized controlled trial of a positive affect intervention for methamphetamine users. Drug Alcohol Depend. 2018;192:8–15.Google Scholar
  12. 12.
    Singer M, Bulled N, Ostrach B, Mendenhall E. Syndemics and the biosocial conception of health. Lancet. 2017;389(10072):941–50.Google Scholar
  13. 13.
    Singer M. AIDS and the health crisis of the US urban poor; the perspective of critical medical anthropology. Soc Sci Med. 1994;39(7):931–48.Google Scholar
  14. 14.
    Meyer JP, Springer SA, Altice FL. Substance abuse, violence, and HIV in women: a literature review of the syndemic. J Womens Health (Larchmt). 2011;20(7):991–1006.Google Scholar
  15. 15.
    Sales JM, Swartzendruber A, Phillips AL. Trauma-informed HIV prevention and treatment. Curr HIV/AIDS Rep. 2016;13(6):374–82.Google Scholar
  16. 16.
    Machtinger EL, Wilson TC, Haberer JE, Weiss DS. Psychological trauma and PTSD in HIV-positive women: a meta-analysis. AIDS Behav. 2012;16(8):2091–100.Google Scholar
  17. 17.
    Leserman J, Pence BW, Whetten K, Mugavero MJ, Thielman NM, Swartz MS, et al. Relation of lifetime trauma and depressive symptoms to mortality in HIV. Am J Psychiatry. 2007;164(11):1707–13.Google Scholar
  18. 18.
    Leserman J. Role of depression, stress, and trauma in HIV disease progression. Psychosom Med. 2008;70(5):539–45.Google Scholar
  19. 19.
    Frattaroli J. Experimental disclosure and its moderators: a meta-analysis. Psychol Bull. 2006;132(6):823–65.Google Scholar
  20. 20.
    Sloan DM, Marx BP, Lee DJ. Written exposure therapy vs cognitive processing therapy-reply. JAMA Psychiatry. 2018;75(7):758–9.Google Scholar
  21. 21.
    Pennebaker JW, Kiecolt-Glaser JK, Glaser R. Disclosure of traumas and immune function: health implications for psychotherapy. J Consult Clin Psychol. 1988;56(2):239–45.Google Scholar
  22. 22.
    Pennebaker JW, Mayne TJ, Francis ME. Linguistic predictors of adaptive bereavement. J Pers Soc Psychol. 1997;72(4):863–71.Google Scholar
  23. 23.
    Pennebaker JW, Susman JR. Disclosure of traumas and psychosomatic processes. Soc Sci Med. 1988;26(3):327–32.Google Scholar
  24. 24.
    Petrie KJ, Fontanilla I, Thomas MG, Booth RJ, Pennebaker JW. Effect of written emotional expression on immune function in patients with human immunodeficiency virus infection: a randomized trial. Psychosom Med. 2004;66(2):272–5.Google Scholar
  25. 25.
    Rivkin ID, Gustafson J, Weingarten I, Chin D. The effects of expressive writing on adjustment to HIV. AIDS Behav. 2006;10(1):13–26.Google Scholar
  26. 26.
    Carrico AW, Nation A, Gomez W, Sundberg J, Dilworth SE, Johnson MO, et al. Pilot trial of an expressive writing intervention with HIV-positive methamphetamine-using men who have sex with men. Psychol Addict Behav. 2015;29(2):277–82.Google Scholar
  27. 27.
    Wagner LJ, Hilker KA, Hepworth JT, Wallston KA. Cognitive adaptability as a moderator of expressive writing effects in an HIV sample. AIDS Behav. 2010;14(2):410–20.Google Scholar
  28. 28.
    Ironson G, O’Cleirigh C, Leserman J, Stuetzle R, Fordiani J, Fletcher M, et al. Gender-specific effects of an augmented written emotional disclosure intervention on posttraumatic, depressive, and HIV-disease-related outcomes: a randomized, controlled trial. J Consult Clin Psychol. 2013;81(2):284–98.Google Scholar
  29. 29.
    Antoni MH, Carrico AW, Duran RE, Spitzer S, Penedo F, Ironson G, et al. Randomized clinical trial of cognitive behavioral stress management on human immunodeficiency virus viral load in gay men treated with highly active antiretroviral therapy. Psychosom Med. 2006;68(1):143–51.Google Scholar
  30. 30.
    Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. J Psychiatr Res. 2011;45(5):626–9.Google Scholar
  31. 31.
    Carrico AW, Nil E, Sophal C, Stein E, Sokunny M, Yuthea N, et al. Behavioral interventions for Cambodian female entertainment and sex workers who use amphetamine-type stimulants. J Behav Med. 2016;39(3):502–10.Google Scholar
  32. 32.
    Weathers FW, Litz BT, Keane TM, Palmieri PA, Marx BP, Schnurr PP. The PTSD Checklist for DSM-5 (PCL-5) 2013. Available from: The National Center for PTSD at www.ptsd.va.gov.
  33. 33.
    Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385–401.Google Scholar
  34. 34.
    Newcombe DAL, Humeniuk RE, Ali R. Validation of the world health organization alcohol, smoking and substance involvement screening test (ASSIST): report of results from the Australian site. Drug Alcohol Rev. 2005;24(3):217–26.Google Scholar
  35. 35.
    Ali RHR. Validation of the alcohol, smoking and substance involvement screening test (ASSIST) and pilot brief intervention: a technical report of phase II findings of the WHO ASSIST Project2006. Available from: http://www.who.int/substance_abuse/activities/assist_technicalreport_phase2_final.pdf.
  36. 36.
    Ling W, Shoptaw S, Wesson D, Rawson RA, Compton M, Klett CJ. Treatment effectiveness score as an outcome measure in clinical trials. NIDA Res Monogr. 1997;175:208–20.Google Scholar
  37. 37.
    Baker TB, Piper ME, McCarthy DE, Majeskie MR, Fiore MC. Addiction motivation reformulated: an affective processing model of negative reinforcement. Psychol Rev. 2004;111(1):33–51.Google Scholar
  38. 38.
    Feaster DJ, Brincks AM, Mitrani VB, Prado G, Schwartz SJ, Szapocznik J. The efficacy of structural ecosystems therapy for HIV medication adherence with African American women. J Fam Psychol. 2010;24(1):51–9.Google Scholar
  39. 39.
    Feaster DJ, Burns MJ, Brincks AM, Prado G, Mitrani VB, Mauer MH, et al. Structural ecosystems therapy for HIV+ African-American women and drug abuse relapse. Fam Process. 2010;49(2):204–19.Google Scholar
  40. 40.
    Feaster DJ, Mitrani VB, Burns MJ, McCabe BE, Brincks AM, Rodriguez AE, et al. A randomized controlled trial of structural ecosystems therapy for HIV medication adherence and substance abuse relapse prevention. Drug Alcohol Depend. 2010;111(3):227–34.Google Scholar
  41. 41.
    Wechsberg WM, Lam WK, Zule WA, Bobashev G. Efficacy of a woman-focused intervention to reduce HIV risk and increase self-sufficiency among African American crack abusers. Am J Public Health. 2004;94(7):1165–73.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Danita Jemison
    • 1
  • Sequoia Jackson
    • 1
  • Olorunleke Oni
    • 2
  • Deva Cats-Baril
    • 1
  • Shawdae Thomas-Smith
    • 3
  • Abigail Batchelder
    • 4
  • Allan Rodriguez
    • 5
  • Samantha E. Dilworth
    • 6
  • Lisa R. Metsch
    • 7
  • Deborah Jones
    • 1
  • Daniel J. Feaster
    • 1
  • Conall O’Cleirigh
    • 4
  • Gail Ironson
    • 8
  • Adam W. Carrico
    • 1
    • 9
    Email author
  1. 1.Department of Public Health Sciences, School of MedicineUniversity of MiamiMiamiUSA
  2. 2.Department of Family MedicineJackson Memorial HospitalMiamiUSA
  3. 3.Department of Family MedicineJohn H. Stroger HospitalChicagoUSA
  4. 4.Department of PsychiatryHarvard Medical School/Massachusetts General HospitalBostonUSA
  5. 5.Department of Medicine, School of MedicineUniversity of MiamiMiamiUSA
  6. 6.Department of Medicine, School of MedicineUniversity of CaliforniaSan FranciscoUSA
  7. 7.Department of Sociomedical Sciences, Mailman School of Public HealthColumbia UniversityNew YorkUSA
  8. 8.Department of Psychology, College of Arts and SciencesUniversity of MiamiCoral GablesUSA
  9. 9.University of Miami Miller School of MedicineMiamiUSA

Personalised recommendations